Efficacy of long-term risankizumab treatment for moderate-to-severe plaque psoriasis: Subgroup analyses by baseline characteristics and psoriatic disease manifestations through 256 weeks (LIMMitless trial).
Bruce E StroberHervé BachelezJeffrey CrowleyBoni E ElewskiMelinda J GooderhamMartin Alan MenterRobert StrohalMichael M ChenTianshuang WuTianyu ZhanHuzefa PhotowalaApril W ArmstrongPublished in: Journal of the European Academy of Dermatology and Venereology : JEADV (2024)
Risankizumab demonstrated generally consistent efficacy through 256 weeks across patient subgroups and showed durable long-term efficacy for psoriatic disease manifestations.